TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3890505

Group type: EXPERIMENTAL
Intervention: Intravenous verapamil (16 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (10 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination therapy (verapamil and metoprolol)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Metoprolol (10 mg) during upright bicycle exercise
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Verapamil (16 mg) during upright bicycle exercise
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination therapy during upright bicycle exercise
Number of subjects: 22
Study: 30797084

Group type: EXPERIMENTAL
Intervention: Dalbavancin 1500 mg intravenously as a single dose
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Dalbavancin 1000 mg followed by 500 mg a week later (two doses)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 698

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 698
Study: 29475792

Group type: EXPERIMENTAL
Intervention: Dressing removed on postoperative day 1 (group A, n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dressing removed on postoperative day 6 (group B, n=40)
Number of subjects: 80
Study: 27632267

Group type: EXPERIMENTAL
Intervention: Immediate loading with two Straumann implants splinted with a Dolder bar, loaded within 48 hours postoperative.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Early loading with two Straumann implants, loaded 6 weeks postoperative.
Number of subjects: 40
Study: 1425713

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg/12 h)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Doxycycline (100 mg/12 h)
Number of subjects: 70
Study: 22880973

Group type: EXPERIMENTAL
Intervention: Combined psychosocial intervention with emergency feeding program
Number of subjects: 147

Group type: COMPARATOR
Intervention: Nutritional support alone (contrast group)
Number of subjects: 147
Study: 20416067

Group type: EXPERIMENTAL
Intervention: Hyperthyroidism (HYPER)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Hypothyroidism (HYPO)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Subclinical hypothyroidism (SCH)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal (N)
Number of subjects: 56
Study: 18689384

Group type: EXPERIMENTAL
Intervention: High-dose potassium citrate (55.5 mEq/d)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Low-dose potassium citrate (18.5 mEq/d)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: 300 g additional fruit and vegetables/d (equivalent of 18.5 mEq alkali)
Number of subjects: 276
Study: 15932387

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with 100 IR grass pollen extract
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with 300 IR grass pollen extract
Number of subjects: 71
Study: 14674834

Group type: EXPERIMENTAL
Intervention: Covering the vomeronasal duct (VND)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not covering the vomeronasal duct (VND)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection thresholds of androstenone
Number of subjects: 0
Study: 10350223

Group type: EXPERIMENTAL
Intervention: Zafirlukast, a cysteinyl leukotriene receptor antagonist, administered for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 0
Study: 8607661

Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg bolus over 2 minutes followed by a 30-minute infusion of 0.375 mg/min and then 0.125 mg/min for 3 days)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 199
Study: 1836595

Group type: EXPERIMENTAL
Intervention: Daily plasma exchanges with fresh frozen plasma (15 ml/kg) in albumin (45 ml/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Daily transfusions of fresh frozen plasma (15 ml/kg)
Number of subjects: 40
Study: 6429905

Group type: EXPERIMENTAL
Intervention: Quarterly supervision of CBD family planning programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monthly supervision of CBD family planning programs
Number of subjects: 0
Study: 31743175

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub applied on gloves every 15 minutes (total of 8 applications)
Number of subjects: 50

Group type: COMPARATOR
Intervention: New, unused gloves (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub on gloves
Number of subjects: 50
Study: 30270019

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strength Training + High-Intensity Interval Training (ST + HIIT)
Number of subjects: 0
Study: 27465148

Group type: EXPERIMENTAL
Intervention: Work-related medical rehabilitation program
Number of subjects: 504

Group type: COMPARATOR
Intervention: Conventional medical rehabilitation program
Number of subjects: 504
Study: 24613436

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (1 × 10(9) CFU, Lactobacillus rhamnosus GG and Bifidobacterium infantis per day for 28 days)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 22071024

Group type: EXPERIMENTAL
Intervention: Community pharmacist osteoporosis screening intervention (education, pamphlets, point‐of‐care quantitative heel ultrasound [QUS])
Number of subjects: 262

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Intervention (education, pamphlets, QUS)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Intervention patients only
Number of subjects: 262
Study: 19875651

Group type: EXPERIMENTAL
Intervention: Group 1 (shorter acclimatization time)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Group 2 (longer acclimatization time)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 25
Study: 17665339

Group type: EXPERIMENTAL
Intervention: Stand-alone cage
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cage + anterior plate fixation
Number of subjects: 37
Study: 17382734

Group type: EXPERIMENTAL
Intervention: 1.5% glycine
Number of subjects: 250

Group type: COMPARATOR
Intervention: 5% glucose
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Glycine assay
Number of subjects: 250
Study: 15624267

Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg/day plus MPA 1.25 mg/day (Group B)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/day plus MPA 2.5 mg/day (Group A)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 11268466

Group type: COMPARATOR
Intervention: Tamoxifen only for 4 years
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus 6 cycles of standard CMF
Number of subjects: 250

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 250
Study: 9180334

Group type: EXPERIMENTAL
Intervention: HA-coated screws
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard screws
Number of subjects: 19
Study: 1490039

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 90

Group type: COMPARATOR
Intervention: Discography
Number of subjects: 90
Study: 2951827

Group type: EXPERIMENTAL
Intervention: Ipratropium 0.5 mg/fenoterol 1.25 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ipratropium 0.5 mg/fenoterol 2.5 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ipratropium 0.5 mg/fenoterol 5.0 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Salbutamol 5.0 mg
Number of subjects: 11
Study: 31707825

Group type: EXPERIMENTAL
Intervention: Off-label claim + pro forma disclaimers
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Off-label claim + evidence context
Number of subjects: 686

Group type: COMPARATOR
Intervention: On-label indication
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Off-label information from the manufacturer
Number of subjects: 686
Study: 27023345

Group type: EXPERIMENTAL
Intervention: Antenatal exercise programme (weekly classes from the 20th week of pregnancy)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no exercise programme)
Number of subjects: 51
Study: 26166655

Group type: EXPERIMENTAL
Intervention: mNGF (mouse nerve growth factor) plus systematic rehabilitation training and GM‐1 intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Systematic rehabilitation training and GM‐1 intervention
Number of subjects: 62
Study: 23062413

Group type: EXPERIMENTAL
Intervention: Low preoperative urine hepcidin concentration (median, 15.3 ng/mL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low preoperative plasma hepcidin concentration (median, 49.2 ng/mL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preoperative serum creatinine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preoperative urine hepcidin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preoperative plasma hepcidin
Number of subjects: 100
Study: 21895700

Group type: EXPERIMENTAL
Intervention: AH Plus + gutta‐percha
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: I Root SP + gutta‐percha
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MTA Fillapex + gutta‐percha
Number of subjects: 30
Study: 19059553

Group type: EXPERIMENTAL
Intervention: Strong Healthy Women intervention
Number of subjects: 692
Study: 17133475

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 673

Group type: COMPARATOR
Intervention: Lamivudine (LVD)
Number of subjects: 673
Study: 14768770

Group type: EXPERIMENTAL
Intervention: Glimepiride (1, 2, 3, 4 or 6 mg once daily, n = 111)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Acarbose (50, 100, 150 or 200 mg 3 times daily, n = 108)
Number of subjects: 219
Study: 10720032

Group type: EXPERIMENTAL
Intervention: High-dose adrenomedullin (5.8 pmol/kg x min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-dose adrenomedullin (2.9 pmol/kg x min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle infusion
Number of subjects: 8
Study: 9022839

Group type: EXPERIMENTAL
Intervention: Weight training program (upper and lower body exercises, twice per week for 20 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Weight training program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 1286596

Group type: EXPERIMENTAL
Intervention: rHuIFN alpha‐1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: rHuIFN alpha‐1 (cumulative cases)
Number of subjects: 100
Study: 4079669

Group type: EXPERIMENTAL
Intervention: Modified amino acid solution enriched in branched-chain amino acids (BAA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional amino acid solution (Azonutril)
Number of subjects: 70
Study: 30783215

Group type: EXPERIMENTAL
Intervention: SPAZ
Number of subjects: 2012

Group type: COMPARATOR
Intervention: SPCQ
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: All women
Number of subjects: 2012
Study: 30419894

Group type: EXPERIMENTAL
Intervention: Community residential aftercare (CRA)
Number of subjects: 41
Study: 26774152

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy combined with intraperitoneal hyperthermic chemoperfusion
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (only systemic chemotherapy)
Number of subjects: 48
Study: 24400998

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) - 559.2 mg total catechins, 120.4 mg caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22997793

Group type: EXPERIMENTAL
Intervention: Ultrastructural acupotomy therapy at the counter‐Ashi points, treatment given once a week for 1 month.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional acupuncture‐moxibustion therapy, treatment given once daily for 1 month.
Number of subjects: 60
Study: 20952270

Group type: EXPERIMENTAL
Intervention: Terminal ligature of ITA branches (group 2)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Truncal ligature of ITA (group 1)
Number of subjects: 126
Study: 17954353

Group type: EXPERIMENTAL
Intervention: Maximal effort grip strength
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Submaximal effort grip strength
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Test-retest reliability of maximal isotonic grip effort for velocity
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ROC curve analysis for sensitivity and specificity
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall test performance
Number of subjects: 32
Study: 15363881

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral self-help treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Follow-up after treatment termination
Number of subjects: 56
Study: 11288822

Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (10-40 mg/day)
Number of subjects: 4406

Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine
Number of subjects: 4406

Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone or in combination
Number of subjects: 4406

Group type: COMPARATOR
Intervention: Monotherapy with nitrendipine
Number of subjects: 4406
Study: 9625908

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether (loading dose of 3.2 mg/kg, followed by 1.6 mg/kg daily for 4 days)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intravenous quinine (loading dose of 20 mg/kg, followed by 10 mg/kg every 8 h for at least 48 h, then oral quinine for a total of 7 days)
Number of subjects: 33
Study: 7955999

Group type: EXPERIMENTAL
Intervention: Diet alone (Group 1)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Diet and oral hypoglycaemic agents (Group 2)
Number of subjects: 204
Study: 3677462

Group type: EXPERIMENTAL
Intervention: Chorionic Villus Sampling (CVS)
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 1254
Study: 28854126

Group type: EXPERIMENTAL
Intervention: Guided error-based learning (n = 37)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Correct motion instruction (n = 38)
Number of subjects: 75
Study: 26706833

Group type: EXPERIMENTAL
Intervention: Exemestane therapy
Number of subjects: 2446

Group type: EXPERIMENTAL
Intervention: Exemestane + Metformin
Number of subjects: 2446

Group type: COMPARATOR
Intervention: Sequential treatment (Tamoxifen followed by Exemestane)
Number of subjects: 2446
Study: 24477478

Group type: EXPERIMENTAL
Intervention: Parent-nominated target problems (PTPs)
Number of subjects: 48
Study: 22542876

Group type: EXPERIMENTAL
Intervention: Neurostimulation intensity 0.2 and 0.5mAmp (Group 1)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Neurostimulation intensity between 0.6 and 1mAmp (Group 2)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Neurostimulation intensity equal or higher than 1.1mAmp (Group 3)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Catheter introduced between 3-5cm without looking for a motor response (Group 4)
Number of subjects: 124
Study: 19855955

Group type: EXPERIMENTAL
Intervention: Increased plasma PAI-1 levels
Number of subjects: 94
Study: 17339122

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) administration
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 16336883

Group type: EXPERIMENTAL
Intervention: Lidocaine 4% cream on both sides of the face
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lidocaine 4% cream on one side of the face
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle cream on both sides of the face
Number of subjects: 24
Study: 11884251

Group type: EXPERIMENTAL
Intervention: Myocardial velocity gradient (MVG) M‐mode Doppler tissue imaging in the noninvasive study group
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Myocardial velocity gradient (MVG) M‐mode Doppler tissue imaging in the invasive study group
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Myocardial velocity gradient (MVG) M‐mode Doppler tissue imaging in the hemodialysis group
Number of subjects: 85
Study: 10235548

Group type: EXPERIMENTAL
Intervention: SITA Standard
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SITA Fast
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: FASTPAC
Number of subjects: 50

Group type: COMPARATOR
Intervention: Full Threshold
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SITA Fast and SITA Standard
Number of subjects: 50
Study: 8732374

Group type: EXPERIMENTAL
Intervention: Anistreplase at home followed by placebo in the hospital (A/P group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo followed by anistreplase (P/A group)
Number of subjects: 100
Study: 1887750

Group type: EXPERIMENTAL
Intervention: Famotidine (0.5 mg.kg-1 per dose, two doses)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Famotidine (0.5 mg.kg-1 per dose, one dose)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (two doses)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Famotidine (one dose) and Placebo (one dose)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Famotidine (any dose)
Number of subjects: 58
Study: 6226186

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methyldopa and hydrochlorothiazide combined
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone
Number of subjects: 32
Study: 31887369

Group type: EXPERIMENTAL
Intervention: Emricasan 5 mg
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Emricasan 50 mg
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 30221589

Group type: EXPERIMENTAL
Intervention: Telephone-delivered cognitive behavioural therapy (TCBT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Face-to-face cognitive behavioural therapy (CBT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Both TCBT and CBT
Number of subjects: 72
Study: 28941657

Group type: COMPARATOR
Intervention: Complex decongestive therapy (CDT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Complex rehabilitation combined with complex decongestive therapy (CRCDT)
Number of subjects: 40
Study: 24643137

Group type: EXPERIMENTAL
Intervention: ALADDIN platform
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 22170885

Group type: EXPERIMENTAL
Intervention: Gufoni maneuver
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Head‐shaking maneuver
Number of subjects: 157

Group type: COMPARATOR
Intervention: Sham maneuver
Number of subjects: 157
Study: 19577008

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 211

Group type: COMPARATOR
Intervention: White Light (WL)
Number of subjects: 211
Study: 17582290

Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 515

Group type: COMPARATOR
Intervention: CCABG
Number of subjects: 515
Study: 15107413

Group type: EXPERIMENTAL
Intervention: Oral glutamine supplement (0.1 g/kg) given four times daily for the first 14 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 11059859

Group type: COMPARATOR
Intervention: Prednisolone (50 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg/day)
Number of subjects: 8
Study: 9113182

Group type: EXPERIMENTAL
Intervention: esmolol 1 mg.kg‐1 + 200 micrograms.kg‐1.min‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 40
Study: 8096956

Group type: EXPERIMENTAL
Intervention: Halofantrine (24 mg/kg)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Mefloquine (25 mg/kg)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Halofantrine (72 mg/kg, 8 mg/kg every 8 h for 3 days)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Halofantrine (72 mg/kg)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: High-dose Halofantrine (72 mg/kg)
Number of subjects: 198
Study: 4036539

Group type: EXPERIMENTAL
Intervention: Atropine 0.03 mg/kg p.o.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atropine 0.02 mg/kg i.m.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 2833543

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (150 mg daily for 6 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Maprotiline (150 mg daily for 6 weeks)
Number of subjects: 44
Study: 29948420

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy plus surgery (CROSS cohort)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy plus surgery (post-CROSS cohort)
Number of subjects: 381
Study: 28879576

Group type: EXPERIMENTAL
Intervention: Heavy-strength training (HST) - 5 sets × 3 repetition maximum (RM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hypertrophy training (HYT) - 3 sets × 12 RM
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Heavy-strength training (HST)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control session (CON)
Number of subjects: 14
Study: 25520426

Group type: EXPERIMENTAL
Intervention: PrEP (daily oral combination tenofovir disoproxil fumarate plus emtricitabine)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 247
Study: 23088178

Group type: EXPERIMENTAL
Intervention: Presurgical cognitive-behavioral stress management (SM)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Supportive attention (SA)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 89
Study: 21389754

Group type: EXPERIMENTAL
Intervention: STEPPS plus adjunctive individual therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 168
Study: 18991076

Group type: EXPERIMENTAL
Intervention: CEE/MPA (1.25 or 2.5 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tibolone (1.25 or 2.5 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CEE/MPA and Tibolone
Number of subjects: 100
Study: 17151160

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 112
Study: 12843685

Group type: EXPERIMENTAL
Intervention: Oral amiodarone (group B)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Oral diltiazem (group A)
Number of subjects: 106

Group type: COMPARATOR
Intervention: No antiarrhythmic drugs (group C)
Number of subjects: 106